Researchers at the Institute of Cancer Research (ICR) in the UK have developed a new blood test to detect the presence of any residual tumours after chemotherapy and radiotherapy in locally advanced (non-metastatic) head and neck cancer patients.

The HPV16-detect test is designed to identify DNA from the human papillomavirus (HPV), which is known to drive the development of head and neck cancer in certain patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Intended to eliminate the need for repeat biopsies, the test could aid in minimising the number of patients with HPV-positive tumours who undergo neck surgery by predicting treatment response.

ICR associate honorary faculty Dr Shreerang Bhide said: “Among cases of head and neck cancer, patients with the HPV-positive disease tend to be younger and have better survival rates.

“This research shows that a blood test for HPV DNA can be used to identify how patients have responded to treatment, and therefore has the potential to spare them unnecessary surgery and significantly improve their quality of life.”

"The new examination detected 86 patients and did not deliver any false positive results for HPV-negative tumours."

The researchers compared the new test with biopsy analysis in 88 head and neck cancer patients.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

While the standard test identified 47 patients with HPV-positive tumours, the new examination detected 86 patients and did not deliver any false positive results for HPV-negative tumours.

The test also found 36 out of 37 patients were tested negative for residual HPV following treatment, while the remaining HPV-positive patient encountered disease recurrence.

PET-CT scans, however, are reported to have detected abnormalities in six treated patients that were later found to be non-cancerous.

Image: Blood samples. Photo: courtesy of the Institute of Cancer Research.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact